Ex-Dividend Alert: West Pharmaceutical Services, Cohen & Steers Tax-Advantaged Preferred Securities, and Home BancShares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy WST?
Source: NASDAQ.COM
Upcoming Ex-Dividend Dates: On 11/12/25, West Pharmaceutical Services (WST), Cohen & Steers Tax-advantaged Preferred Securities (PTA), and Home BancShares Inc (HOMB) will trade ex-dividend, with respective dividends of $0.22, $0.134, and $0.21 scheduled for payment on 11/19/25, 11/28/25, and 12/3/25.
Expected Price Adjustments: Following the ex-dividend dates, WST shares are expected to open 0.08% lower, PTA by 0.67%, and HOMB by 0.76%, based on their recent stock prices.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 0.32% for WST, 8.09% for PTA, and 3.06% for HOMB, indicating varying levels of return for investors.
Market Performance: In recent trading, WST shares are down about 1.6%, while PTA shares have increased by 0.1% and HOMB shares are up by 1.4%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 302.400
Low
285.00
Averages
348.70
High
375.00
Current: 302.400
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High Dividend ETF Investment Strategies
- FDVV ETF Overview: The Fidelity High Dividend ETF has achieved an average annual return of 13.3% since its launch in September 2016, with a current dividend yield of 2.8%, highlighting its appeal in high-dividend investing, although its top four holdings are all tech stocks, which may impact investors' diversification strategies.
- NOBL ETF Advantages: The ProShares S&P 500 Dividend Aristocrats ETF consists of 69 companies that have paid and increased dividends for at least 25 years, offering a dividend yield of 2.09%, nearly double that of the S&P 500 index, and its P/E ratio of 21 is lower than the S&P 500's 31.9, indicating strong fundamentals.
- Fee Comparison: FDVV has an expense ratio of 0.15%, while NOBL charges 0.35%, making FDVV more cost-effective, appealing to long-term investors seeking low-cost high-dividend investment options.
- Investment Recommendation: Although both ETFs have underperformed the S&P 500 index in recent years, FDVV may be more suitable for investors looking to diversify within high-dividend stocks due to its lower fees and higher dividend yield.
See More
West Pharmaceutical Shares Drop Due to Cybersecurity Incident
- Cybersecurity Incident Impact: West Pharmaceutical disclosed in a regulatory filing that unauthorized access to its data has disrupted global business operations, leading to a second consecutive day of stock price decline, reflecting market concerns over operational stability.
- Incident Response Measures: The company activated its incident response protocols, taking global systems offline since the initial breach detection on May 8, notifying law enforcement, and engaging external cybersecurity experts, indicating a serious approach to the incident.
- Business Recovery Progress: While core enterprise systems have been restored, the company is unable to provide a comprehensive timeline for full restoration amid an ongoing investigation, which may negatively impact customer confidence and future revenue.
- Future Outlook: Despite current challenges, West Pharmaceutical projects 2026 revenue between $3.295 billion and $3.35 billion, with adjusted EPS of $8.40 to $8.75, indicating continued growth momentum driven by high-value product (HVP) components.
See More
West Pharmaceutical Services to Present at Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Bank of America Global Healthcare Conference on May 12, 2026, and the William Blair Annual Growth Stock Conference on June 2, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's visibility.
- Webcast Availability: The live webcasts for these events will be accessible in the Investors section of the company's website, with replays available for approximately 90 days post-event, enhancing transparency and fostering interaction with potential investors.
- Company Performance Overview: West reported net sales of $3.07 billion in fiscal year 2025, demonstrating strong performance in the global injectable solutions market, further solidifying its position as an industry leader.
- Global Business Footprint: With over 10,000 employees across 50 sites, including 26 manufacturing facilities, West delivers over 41 billion components and devices annually, enabling effective support for drug developers and enhancing its competitive edge in the market.
See More
Analysis of WST Dividend Expectations and Stock Performance
- Dividend Yield Analysis: WST's estimated annualized dividend yield stands at 0.29%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
- Stock Price Range: WST's 52-week low is $202.79 per share, with a high of $322.34, and the latest trade at $308.61 indicates that the stock is fluctuating near its high, which may affect investors' buying decisions.
- ETF Holding Proportion: According to ETF Channel, WST constitutes 4.44% of the Virtus KAR Mid-Cap ETF (KMID), which is trading down about 0.4% on the day, potentially reflecting overall market sentiment towards mid-cap stocks.
- Intraday Stock Performance: In Monday trading, shares of West Pharmaceutical Services, Inc. are up about 0.7%, indicating a positive short-term market reaction to the company, which may attract more investor attention.
See More
BARCLAYS INCREASES TARGET PRICE FOR WEST PHARMACEUTICAL SERVICES INC TO $310, UP FROM $275
Company Overview: West Pharmaceutical Services is a key player in the pharmaceutical industry, providing essential services and products.
Target Price Increase: Barclays has raised the target price for West Pharmaceutical Services from $275 to $310, indicating a positive outlook for the company's stock.
See More
Semiconductor Stocks Overbought Amid Market Rally
- Semiconductor Surge: Semiconductor stocks emerged as a focal point for investors this week, with the S&P 500 and Nasdaq rising 0.55% and 1.50% respectively, pushing the market to new highs and reflecting strong optimism in the sector.
- Overbought Indicators: CNBC Pro's analysis identified stocks with a 14-day RSI above 70 as overbought, indicating potential pullback risks, particularly as the iShares Semiconductor ETF (SOXX) posted an 11.04% gain this week, showcasing robust enthusiasm for chipmakers.
- Earnings Drive: Texas Instruments reported first-quarter earnings that exceeded expectations, highlighting strong demand for its analog chips, which significantly boosted its stock price and reinforced market confidence in the semiconductor industry.
- Narrowing Market Leadership: Cameron Dawson, Chief Investment Officer at NewEdge Wealth, noted that market leadership is increasingly concentrated in the semiconductor sector, indicating a sustained rise in investor focus on this industry, which may impact the performance of other sectors.
See More
Analysis of High Dividend ETF Investment Strategies
- FDVV ETF Overview: The Fidelity High Dividend ETF has achieved an average annual return of 13.3% since its launch in September 2016, with a current dividend yield of 2.8%, highlighting its appeal in high-dividend investing, although its top four holdings are all tech stocks, which may impact investors' diversification strategies.
- NOBL ETF Advantages: The ProShares S&P 500 Dividend Aristocrats ETF consists of 69 companies that have paid and increased dividends for at least 25 years, offering a dividend yield of 2.09%, nearly double that of the S&P 500 index, and its P/E ratio of 21 is lower than the S&P 500's 31.9, indicating strong fundamentals.
- Fee Comparison: FDVV has an expense ratio of 0.15%, while NOBL charges 0.35%, making FDVV more cost-effective, appealing to long-term investors seeking low-cost high-dividend investment options.
- Investment Recommendation: Although both ETFs have underperformed the S&P 500 index in recent years, FDVV may be more suitable for investors looking to diversify within high-dividend stocks due to its lower fees and higher dividend yield.
See More
West Pharmaceutical Shares Drop Due to Cybersecurity Incident
- Cybersecurity Incident Impact: West Pharmaceutical disclosed in a regulatory filing that unauthorized access to its data has disrupted global business operations, leading to a second consecutive day of stock price decline, reflecting market concerns over operational stability.
- Incident Response Measures: The company activated its incident response protocols, taking global systems offline since the initial breach detection on May 8, notifying law enforcement, and engaging external cybersecurity experts, indicating a serious approach to the incident.
- Business Recovery Progress: While core enterprise systems have been restored, the company is unable to provide a comprehensive timeline for full restoration amid an ongoing investigation, which may negatively impact customer confidence and future revenue.
- Future Outlook: Despite current challenges, West Pharmaceutical projects 2026 revenue between $3.295 billion and $3.35 billion, with adjusted EPS of $8.40 to $8.75, indicating continued growth momentum driven by high-value product (HVP) components.
See More
West Pharmaceutical Services to Present at Upcoming Investor Conferences
- Investor Conference Schedule: West Pharmaceutical Services will participate in the Bank of America Global Healthcare Conference on May 12, 2026, and the William Blair Annual Growth Stock Conference on June 2, 2026, showcasing its innovative solutions in injectable drug administration, which is expected to attract investor interest and enhance the company's visibility.
- Webcast Availability: The live webcasts for these events will be accessible in the Investors section of the company's website, with replays available for approximately 90 days post-event, enhancing transparency and fostering interaction with potential investors.
- Company Performance Overview: West reported net sales of $3.07 billion in fiscal year 2025, demonstrating strong performance in the global injectable solutions market, further solidifying its position as an industry leader.
- Global Business Footprint: With over 10,000 employees across 50 sites, including 26 manufacturing facilities, West delivers over 41 billion components and devices annually, enabling effective support for drug developers and enhancing its competitive edge in the market.
See More
Analysis of WST Dividend Expectations and Stock Performance
- Dividend Yield Analysis: WST's estimated annualized dividend yield stands at 0.29%, and while dividends are not always predictable, historical data aids in assessing the likelihood of future dividends, thereby influencing investor return expectations.
- Stock Price Range: WST's 52-week low is $202.79 per share, with a high of $322.34, and the latest trade at $308.61 indicates that the stock is fluctuating near its high, which may affect investors' buying decisions.
- ETF Holding Proportion: According to ETF Channel, WST constitutes 4.44% of the Virtus KAR Mid-Cap ETF (KMID), which is trading down about 0.4% on the day, potentially reflecting overall market sentiment towards mid-cap stocks.
- Intraday Stock Performance: In Monday trading, shares of West Pharmaceutical Services, Inc. are up about 0.7%, indicating a positive short-term market reaction to the company, which may attract more investor attention.
See More
BARCLAYS INCREASES TARGET PRICE FOR WEST PHARMACEUTICAL SERVICES INC TO $310, UP FROM $275
Company Overview: West Pharmaceutical Services is a key player in the pharmaceutical industry, providing essential services and products.
Target Price Increase: Barclays has raised the target price for West Pharmaceutical Services from $275 to $310, indicating a positive outlook for the company's stock.
See More
Semiconductor Stocks Overbought Amid Market Rally
- Semiconductor Surge: Semiconductor stocks emerged as a focal point for investors this week, with the S&P 500 and Nasdaq rising 0.55% and 1.50% respectively, pushing the market to new highs and reflecting strong optimism in the sector.
- Overbought Indicators: CNBC Pro's analysis identified stocks with a 14-day RSI above 70 as overbought, indicating potential pullback risks, particularly as the iShares Semiconductor ETF (SOXX) posted an 11.04% gain this week, showcasing robust enthusiasm for chipmakers.
- Earnings Drive: Texas Instruments reported first-quarter earnings that exceeded expectations, highlighting strong demand for its analog chips, which significantly boosted its stock price and reinforced market confidence in the semiconductor industry.
- Narrowing Market Leadership: Cameron Dawson, Chief Investment Officer at NewEdge Wealth, noted that market leadership is increasingly concentrated in the semiconductor sector, indicating a sustained rise in investor focus on this industry, which may impact the performance of other sectors.
See More
